Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles

D. H. Park, B. K. Jung, Y. S. Lee, J. Y. Jang, M. K. Kim, J. K. Lee, H. Park, Jongbum Seo, C. W. Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Gene therapy using RNA interference can be directed against tumors through various strategies, but has been hindered owing to the inefficiency of non-viral delivery. To evaluate the antitumor effects of adenine nucleotide translocase-2 (ANT2) short hairpin RNA (shRNA) by intraperitoneal injection using the polyethylenimine (PEI) and an ultrasound gene delivery method, human breast carcinoma MDA-MB-231 cells were injected subcutaneously into NOG (NOD/Shi-scid/IL-2Rγ null) mice. The results showed greater tumor regression (∗P<0.05) as well as an increased survival rate in the group receiving ANT2 shRNA+two types of enhancer relative to the groups receiving ANT2 shRNA without enhancer. These findings demonstrate that the introduction of PEI and ultrasound with SonoVue exerted enhanced antitumor effects in vivo. Although the combination of jet-PEI and ultrasound provided the best results with respect to tumor regression, the antitumor effects from the individual enhancers were approximately equivalent. In addition, we confirmed that there was no toxicity on aspartate aminotransferase and alanine aminotransferase levels in the liver and albumin, blood urea nitrogen or creatine kinase levels in the kidney following the various gene delivery methods.

Original languageEnglish
Pages (from-to)325-332
Number of pages8
JournalGene Therapy
Volume22
Issue number4
DOIs
Publication statusPublished - 2015 Apr 4

Fingerprint

ATP Translocases Mitochondrial ADP
Polyethyleneimine
Microbubbles
Small Interfering RNA
Neoplasms
Blood Urea Nitrogen
Creatine Kinase
Aspartate Aminotransferases
RNA Interference
Intraperitoneal Injections
Alanine Transaminase
Genetic Therapy
Genes
Albumins
Breast Neoplasms
Kidney
Liver

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Park, D. H., Jung, B. K., Lee, Y. S., Jang, J. Y., Kim, M. K., Lee, J. K., ... Kim, C. W. (2015). Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles. Gene Therapy, 22(4), 325-332. https://doi.org/10.1038/gt.2014.120
Park, D. H. ; Jung, B. K. ; Lee, Y. S. ; Jang, J. Y. ; Kim, M. K. ; Lee, J. K. ; Park, H. ; Seo, Jongbum ; Kim, C. W. / Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles. In: Gene Therapy. 2015 ; Vol. 22, No. 4. pp. 325-332.
@article{b39cf10db0a14f63aab87b99b80a9ccd,
title = "Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles",
abstract = "Gene therapy using RNA interference can be directed against tumors through various strategies, but has been hindered owing to the inefficiency of non-viral delivery. To evaluate the antitumor effects of adenine nucleotide translocase-2 (ANT2) short hairpin RNA (shRNA) by intraperitoneal injection using the polyethylenimine (PEI) and an ultrasound gene delivery method, human breast carcinoma MDA-MB-231 cells were injected subcutaneously into NOG (NOD/Shi-scid/IL-2Rγ null) mice. The results showed greater tumor regression (∗P<0.05) as well as an increased survival rate in the group receiving ANT2 shRNA+two types of enhancer relative to the groups receiving ANT2 shRNA without enhancer. These findings demonstrate that the introduction of PEI and ultrasound with SonoVue exerted enhanced antitumor effects in vivo. Although the combination of jet-PEI and ultrasound provided the best results with respect to tumor regression, the antitumor effects from the individual enhancers were approximately equivalent. In addition, we confirmed that there was no toxicity on aspartate aminotransferase and alanine aminotransferase levels in the liver and albumin, blood urea nitrogen or creatine kinase levels in the kidney following the various gene delivery methods.",
author = "Park, {D. H.} and Jung, {B. K.} and Lee, {Y. S.} and Jang, {J. Y.} and Kim, {M. K.} and Lee, {J. K.} and H. Park and Jongbum Seo and Kim, {C. W.}",
year = "2015",
month = "4",
day = "4",
doi = "10.1038/gt.2014.120",
language = "English",
volume = "22",
pages = "325--332",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "4",

}

Park, DH, Jung, BK, Lee, YS, Jang, JY, Kim, MK, Lee, JK, Park, H, Seo, J & Kim, CW 2015, 'Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles', Gene Therapy, vol. 22, no. 4, pp. 325-332. https://doi.org/10.1038/gt.2014.120

Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles. / Park, D. H.; Jung, B. K.; Lee, Y. S.; Jang, J. Y.; Kim, M. K.; Lee, J. K.; Park, H.; Seo, Jongbum; Kim, C. W.

In: Gene Therapy, Vol. 22, No. 4, 04.04.2015, p. 325-332.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles

AU - Park, D. H.

AU - Jung, B. K.

AU - Lee, Y. S.

AU - Jang, J. Y.

AU - Kim, M. K.

AU - Lee, J. K.

AU - Park, H.

AU - Seo, Jongbum

AU - Kim, C. W.

PY - 2015/4/4

Y1 - 2015/4/4

N2 - Gene therapy using RNA interference can be directed against tumors through various strategies, but has been hindered owing to the inefficiency of non-viral delivery. To evaluate the antitumor effects of adenine nucleotide translocase-2 (ANT2) short hairpin RNA (shRNA) by intraperitoneal injection using the polyethylenimine (PEI) and an ultrasound gene delivery method, human breast carcinoma MDA-MB-231 cells were injected subcutaneously into NOG (NOD/Shi-scid/IL-2Rγ null) mice. The results showed greater tumor regression (∗P<0.05) as well as an increased survival rate in the group receiving ANT2 shRNA+two types of enhancer relative to the groups receiving ANT2 shRNA without enhancer. These findings demonstrate that the introduction of PEI and ultrasound with SonoVue exerted enhanced antitumor effects in vivo. Although the combination of jet-PEI and ultrasound provided the best results with respect to tumor regression, the antitumor effects from the individual enhancers were approximately equivalent. In addition, we confirmed that there was no toxicity on aspartate aminotransferase and alanine aminotransferase levels in the liver and albumin, blood urea nitrogen or creatine kinase levels in the kidney following the various gene delivery methods.

AB - Gene therapy using RNA interference can be directed against tumors through various strategies, but has been hindered owing to the inefficiency of non-viral delivery. To evaluate the antitumor effects of adenine nucleotide translocase-2 (ANT2) short hairpin RNA (shRNA) by intraperitoneal injection using the polyethylenimine (PEI) and an ultrasound gene delivery method, human breast carcinoma MDA-MB-231 cells were injected subcutaneously into NOG (NOD/Shi-scid/IL-2Rγ null) mice. The results showed greater tumor regression (∗P<0.05) as well as an increased survival rate in the group receiving ANT2 shRNA+two types of enhancer relative to the groups receiving ANT2 shRNA without enhancer. These findings demonstrate that the introduction of PEI and ultrasound with SonoVue exerted enhanced antitumor effects in vivo. Although the combination of jet-PEI and ultrasound provided the best results with respect to tumor regression, the antitumor effects from the individual enhancers were approximately equivalent. In addition, we confirmed that there was no toxicity on aspartate aminotransferase and alanine aminotransferase levels in the liver and albumin, blood urea nitrogen or creatine kinase levels in the kidney following the various gene delivery methods.

UR - http://www.scopus.com/inward/record.url?scp=84926409743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926409743&partnerID=8YFLogxK

U2 - 10.1038/gt.2014.120

DO - 10.1038/gt.2014.120

M3 - Article

VL - 22

SP - 325

EP - 332

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 4

ER -